Date: Monday, Aug 17, 2020
Description: Dr Januzzi discusses how current evidence supports a causal association between low HDL-C (high-density lipoprotein cholesterol) and cardiovascular risk, and that therapeutic targeting of low HDL-C may be beneficial. However, multiple clinical trials for therapies that increase HDL-C levels have failed to produce positive results. These failed clinical trials have led to the consensus that understanding the function of HDL—not just its levels—is needed to determine and develop effective treatment.
We invite you to join us for a discussion on:
- What is known about HDL and its role in atherosclerosis?
- A novel tool that allows for rapid assessment of HDL function for use in clinical practice
- The relation of the HDLfx panel with pCAD score to other cardiovascular risk markers
- A clinical perspective of HDLfx
ASCLS P.A.C.E.® credits are available to laboratory professionals through February 16, 2021.